Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference
04 Setembro 2007 - 9:00AM
PR Newswire (US)
WESTMINSTER, Colo., Sept. 4 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company
focused on the development and commercialization of small molecule
therapeutics for the treatment of cancer, today announced that Paul
L. Berns, President and CEO, will present a corporate overview at
the Bear Stearns 20th Annual Healthcare Conference in New York. The
Company's presentation will take place at 9:00 a.m. (Eastern) on
Monday, September 10, 2007. There will be a live webcast of the
presentation, which will be accessible through a link posted on the
Allos website home page and investor relations section. The webcast
will be available for replay on Allos' website through September
21, 2007. About Allos Therapeutics, Inc. Allos Therapeutics is a
biopharmaceutical company focused on the development and
commercialization of small molecule therapeutics for the treatment
of cancer. The Company's lead product candidate, PDX
(pralatrexate), is a novel antifolate currently under evaluation in
a pivotal Phase 2 trial in patients with relapsed or refractory
peripheral T-cell lymphoma. The Company is also investigating PDX
in patients with non-small cell lung cancer and a range of other
lymphoma sub-types. The Company's other product candidate is RH1, a
targeted chemotherapeutic agent, for which the company expects to
initiate a Phase 1 trial in patients with advanced solid tumors in
the second half of 2007. For additional information, please visit
the Company's website at http://www.allos.com/. Safe Harbor
Statement The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward- looking
statements is contained in the "Risk Factors" section of the
Company's Annual Report on Form 10-K for the year ended December
31, 2006 and in the Company's other periodic reports and filings
with the Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in the presentation. All forward-looking
statements are based on information currently available to the
Company on the date thereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this
presentation, except as required by law. DATASOURCE: Allos
Therapeutics, Inc. CONTACT: Derek Cole, Vice President, Investor
Relations, +1-720-540-5367, , or Jennifer Neiman, Senior Manager,
Corporate Communications, +1-720-540-5227, , both of Allos
Therapeutics, Inc. Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics (MM)